Table_2_Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population.docx

A few studies examined the comparative side effects of Coronavirus Disease-19 (COVID-19) vaccines. We compared the extension and severity of self-reported side effects of seven COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac Life Sciences), Gam-COVID-Vac (Gamaleya's Sputnik V), Ad5-nCoV (CanSinoBIO), and Ad26.CoV2.S (Johnson & Johnson/Janssen)] in the Mexican population. We also evaluated the association of type of vaccine, sex, age, comorbidity, and history of allergies to the extent and severity of side effects. This was a cross-sectional study carried out online between August 12 and September 3, 2021 in Mexico. The first inclusion criterion was to receive a COVID-19 vaccine and the second, being at least 18 years old. The survey link was distributed via multiple social media platforms. We questioned about the type of vaccine and symptoms based on short-term side effects reported in the literature. Side effect extension was classified as local, systemic, or both. We asked about the need to take medicine, stop activities/miss work, or seek medical attention. Then, a severity index was constructed based on responses. Descriptive and stepwise multivariate logistic ordinal regression analyses were used to calculate odds ratio (OR) and 95% CI for each outcome adjusted by potential confounders. The mean age was 38.9 ± 11.0 years (n = 4,024). Prevalence of at least one side effect varied between vaccines and by a number of doses. At dose 1, ChAdOx1 was the vaccine with the highest rate of at least one side effect (85%) followed by Gam-COVID-Vac (80%). Both were associated to greater extension (adjusted OR 2.53, 95% CI 2.16, 2.96 and adjusted OR 2.41, 95% CI 1.76, 3.29, respectively) and severity of side effects (adjusted OR 4.32, 95% CI 3.73, 5.00 and adjusted OR 3.00, 95% CI 2.28, 3.94, respectively). Young age (

数项研究探讨了新型冠状病毒肺炎（COVID-19）疫苗的相对副作用。本研究对比了七种COVID-19疫苗（包括BNT162b2（辉瑞-BioNTech）、ChAdOx1（阿斯利康）、mRNA-1273（莫德纳）、CoronaVac（科兴生物）、Gam-COVID-Vac（加马列亚的斯普特尼克V）、Ad5-nCoV（康希诺生物）和Ad26.CoV2.S（强生/杨森））在墨西哥人群中的自报副作用之延续性与严重性。此外，本研究还评估了疫苗类型、性别、年龄、合并症以及过敏史与副作用之程度及严重性之间的关联。该研究是一项于2021年8月12日至9月3日在线进行的横断面研究。纳入标准首先为接种COVID-19疫苗，其次为年龄至少18岁。调查链接通过多个社交媒体平台进行分发。我们针对文献中报道的短期副作用，对疫苗类型和症状进行了询问。副作用之延续性被归类为局部、全身或两者兼具。我们还询问了是否需要用药、停止活动/缺勤或寻求医疗帮助。随后，基于回答构建了一个严重性指数。本研究采用了描述性和逐步多元逻辑序数回归分析，以计算每个结果的几率比（OR）和95%置信区间，并对潜在混杂因素进行调整。平均年龄为38.9 ± 11.0岁（n = 4,024）。至少一种副作用的发生率在不同疫苗和剂次之间有所差异。在第一剂次中，ChAdOx1疫苗至少一种副作用的发生率最高（85%），其次是Gam-COVID-Vac（80%）。两者均与副作用之更大延续性（调整后的OR 2.53，95% CI 2.16, 2.96及调整后的OR 2.41，95% CI 1.76, 3.29，分别）和严重性（调整后的OR 4.32，95% CI 3.73, 5.00及调整后的OR 3.00，95% CI 2.28, 3.94，分别）相关联。年轻年龄（